オプションチェーンは、Checkpoint Therapeuticsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Checkpoint Therapeuticsの市場センチメントを評価します。.

Checkpoint Therapeutics (NASDAQ:CKPT) 株価情報, オプションチェーン

Checkpoint Therapeutics

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Checkpoint Therapeutics, Inc. - Common Stock

Checkpoint Therapeutics Inc

Yalla Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YALA#NYSE">YALA</a>) reported quarterly earnings of $0.20 per share. This is a 5.26 percent increase over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $90.83 million which beat the analyst consensus estimate of $83.22 million by 9.14 percent. This is a 12.24 percent increase over sales of $80.92 million the same period last year.

Earnings

Earnings Beats

News

YALA

Yalla Group Q4 2024 Adj EPS $0.20 Up From $0.19 YoY, Sales $90.83M Beat $83.22M Estimate

RMBS

Rambus Unveils Its Next-generation CryptoManager Security IP Solutions, Including Root Of Trust, Hub And Core Families

The acquisition is expected to close in the second quarter of 2025, subject to customary closing conditions and regulatory approval.

Teradyne Agrees To Acquire Privately Held Photonic IC Testing Company Quantifi Photonics; No Terms Disclosed

Outlook
For the first quarter of 2025, Yalla currently expects revenues to be between US$75.0 million and US$82.0 million.
The above outlook is based on current market conditions and reflects the Company management's current and preliminary estimates of market and operating conditions and customer demand, which are all subject to change.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">
[6]&nbsp;Non-GAAP operating income represents operating income excluding share-based compensation. Non-GAAP operating income is a non-GAAP financial measure. See the sections entitled "Non-GAAP Financial Measures" and "Reconciliations of GAAP and Non-GAAP Results" for more information about the non-GAAP measures referred to in this press release.
[7] Non-GAAP earnings per ordinary share is non-GAAP net income attributable to Yalla Group Limited's shareholders, divided by weighted average number of basic and diluted shares outstanding. Non-GAAP net income attributable to Yalla Group Limited's shareholders represents net income attributable to Yalla Group Limited's shareholders, excluding share-based compensation. Non-GAAP earnings per ordinary share and non-GAAP net income attributable to Yalla Group Limited's shareholders are non-GAAP financial measures. See the sections entitled "Non-GAAP Financial Measures" and "Reconciliations of GAAP and Non-GAAP Results" for more information about the non-GAAP measures referred to in this press release.
</td>
</tr>
</tbody>
</table>
</figure>

Guidance

Yalla Group Sees Q1 2025 Revenue $75M-$82M Vs $83.3M Est.

Across the recent three months, 9 analysts have shared their insights on Repay Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPAY#NASDAQ">RPAY</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Repay Holdings and provided 12-month price targets. The average target is $10.5, accompanied by a high estimate of $14.00 and a low estimate of $7.50. Experiencing a 9.56% decline, the current average is now lower than the previous average price target of $11.61. 
<img src="https://www.benzinga.com/files/images/story/2025/1741640666_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Repay Holdings by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$9.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Peter Heckmann</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Rufus Hone</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Timothy Chiodo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$7.50</td>
<td>$9.50</td>
</tr>
<tr>
<td>Charles Nabhan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Peter Heckmann</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Repay Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Repay Holdings compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Repay Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Repay Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RPAY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Repay Holdings analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Repay Holdings's Background</h2>
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.
<h3>Unraveling the Financial Story of Repay Holdings</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Repay Holdings's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 3.01%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -5.26%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Repay Holdings's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.54% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Repay Holdings's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.26% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.67.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

RPAY

Expert Outlook: Repay Holdings Through The Eyes Of 9 Analysts

Throughout the last three months, 18 analysts have evaluated Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $15.22, along with a high estimate of $20.00 and a low estimate of $12.00. Highlighting a 19.13% decrease, the current average has fallen from the previous average price target of $18.82. 
<img src="https://www.benzinga.com/files/images/story/2025/1741640658_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Evolent Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>Citizens Capital Markets</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Jeff Jones</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$16.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$18.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Matthew Sheerin</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Evolent Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Evolent Health compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Evolent Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Evolent Health's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EVH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Evolent Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Evolent Health</h2>
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
<h3>Evolent Health's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Evolent Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.27% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Evolent Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -4.74%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Evolent Health's ROE stands out, surpassing industry averages. With an impressive ROE of -3.0%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Evolent Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.21% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Evolent Health's debt-to-equity ratio is below the industry average at 0.71, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 18 Analysts Discuss Evolent Health Stock

Across the recent three months, 4 analysts have shared their insights on Zymeworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $16.0, along with a high estimate of $19.00 and a low estimate of $13.00. Witnessing a positive shift, the current average has risen by 14.29% from the previous average price target of $14.00.
<img src="https://www.benzinga.com/files/images/story/2025/1741640648_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Zymeworks among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Brian Cheng</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$18.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Zymeworks. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Zymeworks compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Zymeworks's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Zymeworks's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ZYME/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Zymeworks analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Zymeworks</h2>
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
<h3>Breaking Down Zymeworks's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Zymeworks's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 83.33%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Zymeworks's net margin excels beyond industry benchmarks, reaching -75.75%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Zymeworks's ROE excels beyond industry benchmarks, reaching -6.66%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Zymeworks's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -4.95%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.05, Zymeworks adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ZYME

Deep Dive Into Zymeworks Stock: Analyst Perspectives (4 Ratings)

Yalla Group Q4 Adj $0.20 Up From $0.19 YoY, Sales $90.83M Beat $83.22M Estimate

In the last three months, 4 analysts have published ratings on Sun Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Sun Communities, presenting an average target of $137.5, a high estimate of $142.00, and a low estimate of $131.00. A decline of 4.01% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1741640639_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Sun Communities is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Hau</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$142.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Peter Abramowitz</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$142.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>James Feldman</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$135.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Anthony Hau</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$131.00</td>
<td>$138.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sun Communities. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sun Communities compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Sun Communities's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SUI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sun Communities analyst ratings.</a>
<h2>Delving into Sun Communities's Background</h2>
Sun Communities is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently owns a portfolio of 666 properties, which includes 350 manufactured housing communities, 179 residential vehicle communities, and 137 marina properties. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.
<h3>A Deep Dive into Sun Communities's Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Sun Communities's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 2.59%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: Sun Communities's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -30.08%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -3.07%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Sun Communities's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.32%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Sun Communities's debt-to-equity ratio is below the industry average. With a ratio of 1.04, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 4 Analyst Ratings Have To Say About Sun Communities

Viemed Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) reported quarterly earnings of $0.10 per share which met the analyst consensus estimate. This is a 11.11 percent increase over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $60.70 million which beat the analyst consensus estimate of $59.95 million by 1.24 percent. This is a 19.62 percent increase over sales of $50.74 million the same period last year.

Viemed Healthcare Q4 2024 GAAP EPS $0.10, Inline, Sales $60.70M Beat $59.95M Estimate

WIIM

ORCL

Oracle shares are trading higher after the company announced it will increase its quarterly dividend by $0.10 per share.

FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for FactSet Research Systems, revealing an average target of $482.29, a high estimate of $518.00, and a low estimate of $409.00. This current average has increased by 0.12% from the previous average price target of $481.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1741640589_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of FactSet Research Systems's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$503.00</td>
<td>$503.00</td>
</tr>
<tr>
<td>Jason Haas</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$450.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Jason Haas</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$500.00</td>
<td>$503.00</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$518.00</td>
<td>$521.00</td>
</tr>
<tr>
<td>Shlomo Rosenbaum</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$493.00</td>
<td>$469.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$503.00</td>
<td>$503.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$409.00</td>
<td>$373.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to FactSet Research Systems. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of FactSet Research Systems compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of FactSet Research Systems's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of FactSet Research Systems's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FDS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on FactSet Research Systems analyst ratings.</a>
<h2>Delving into FactSet Research Systems's Background</h2>
FactSet provides financial data and portfolio analytics to the Global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for 82% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.
<h3>FactSet Research Systems's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining FactSet Research Systems's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4.88% as of 30 November, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: FactSet Research Systems's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 26.38% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): FactSet Research Systems's ROE excels beyond industry benchmarks, reaching 7.69%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.7%, the company showcases effective utilization of assets.
Debt Management: FactSet Research Systems's debt-to-equity ratio is below the industry average. With a ratio of 0.78, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying FactSet Research Systems: Insights From 7 Analyst Reviews

Commercial Vehicle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGI#NASDAQ">CVGI</a>) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.07) by 114.29 percent. The company reported quarterly sales of $163.30 million which beat the analyst consensus estimate of $158.36 million by 3.12 percent.&nbsp;

Earnings Misses

CVGI

Commercial Vehicle Group Q4 2024 Adj EPS $(0.15) Misses $(0.07) Estimate, Sales $163.30M Beat $158.36M Estimate

The bond market is flashing warning signs, and investors are taking notice. <a href="https://www.benzinga.com/markets/25/03/44211421/us-economy-teetering-recession-may-be-looming-as-bond-market-reacts-to-trump-policies">Short-term Treasury yields have dipped sharply</a> as concerns about an economic slowdown grow, and analysts warn that a Federal Reserve rate cut may be on the horizon. Historically, signals like these have preceded recessions, prompting investors to shift toward defensive assets.
For those looking to safeguard their portfolios,<a href="https://www.benzinga.com/etfs"> ETFs that focus on stability</a> and essential industries can be a smart choice. Whether it&#8217;s low-volatility stocks, utilities, consumer staples, or government bonds, these ETFs help minimize risk while keeping your money at work. Let's explore the top options for weathering a potential downturn.
1. iShares MSCI USA Min Vol Factor ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/USMV#BATS">USMV</a>)
For investors looking to stay in the stock market but reduce risk, the iShares MSCI USA Min Vol Factor ETF is a strong pick. This ETF focuses on large- and mid-cap stocks that have historically exhibited lower volatility. It's designed to limit downside risk, making it a great choice for risk-averse investors.
USMV's portfolio includes firms from sectors like technology, financials, healthcare, and consumer staples. While this ETF helps shield investors from large losses during downturns, it also means less upside potential in booming markets. USMV has a year-to-date return of 5.5% and a 12-month return of 13.5%, proving its ability to hold up well in uncertain times. During the downturn of 2020, this ETF was able to pare the losses within a year of its 2020 peak (February 21, 2020).
Also Read: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/03/44165367/how-to-ride-out-market-turbulence-with-these-5-low-beta-etfs">How To Ride Out Market Turbulence With These 5 Low-Beta ETFs</a>
2. Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)
The utilities sector is often a safe haven during economic downturns. The Utilities Select Sector SPDR Fund offers diversified exposure to this sector, holding 31 companies. Its top five positions make up about 39% of its portfolio.
XLU has a low expense ratio of 0.09% and provides a dividend yield of 2.8% as of 2025. Since utility services like electricity and water remain in demand regardless of economic conditions, this ETF is a solid defensive choice. Over the past year, the ETF has delivered a 21.71% return.
3. Vanguard Consumer Staples ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VDC#NYSE">VDC</a>)
Consumer staples companies produce essential goods like food, beverages, and household products, which people buy regardless of the economic climate. The Vanguard Consumer Staples ETF offers exposure to this sector, holding 103 stocks while balancing exposure to industry giants like Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) and Costco Wholesale Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>).
With an expense ratio of just 0.09%, VDC is an affordable way to invest in recession-resistant stocks. While consumer staples ETFs tend to be top-heavy, VDC provides a well-rounded mix of large and mid-sized companies.
The Market Signals You Should Watch
While defensive ETFs can help protect your portfolio, it's also important to understand why recession concerns are growing.
Investors have been moving into short-dated Treasuries, signaling concerns about an economic slowdown. Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-03-09/the-bond-market-s-trump-trade-is-looking-like-a-recession-trade?srnd=homepage-americas&amp;sref=TBDibEcD">reports </a>that the Federal Reserve may start cutting interest rates as early as May to counteract slowing growth.
The inverted yield curve, where short-term bond yields exceed long-term yields, flashed warning signs in February, as the spread between three-month treasury yields and those of 10-year notes inverted last week. Historically, this has been a strong predictor of a recession knocking at the door. The curve had inverted in 2019, right before the economic downturn in 2020, according to Reuters.
Meanwhile, indicators such as the CNN Fear &amp; Greed Index <a href="https://edition.cnn.com/2025/03/10/investing/us-stocks-drop-after-trump-says-he-wont-rule-out-a-recession/index.html">dropping </a>into &#8220;Extreme Fear&#8221; territory and the Cboe Volatility Index (VIX) <a href="https://www.msn.com/en-us/money/markets/vix-surge-above-25-implies-above-average-but-far-from-perilous-recession-risk/ar-AA1ACR21?ocid=finance-verthp-feeds">spiking </a>to more than 25 reflect heightened investor anxiety.
Even Warren Buffett seems cautious, as Berkshire Hathaway is<a href="https://www.benzinga.com/markets/equities/25/03/44212672/jamie-dimon-cashed-out-234-million-in-jpmorgan-stock-warren-buffett-stockpiled-334-billion-in-cash-weeks-later-markets-crashed-coincidence"> sitting on record cash reserves</a> while trimming long-held positions.
Final Thoughts: Stay Prepared
Preparing your portfolio in advance rather than reacting at the last minute can help mitigate potential losses during economic downturns. Incorporating low-volatility equity ETFs, utility, and consumer staples funds can provide a more resilient foundation.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44224174/wall-streets-worst-week-since-september-5-etfs-that-defied-the-market-slump">Wall Street&#8217;s Worst Week Since September: 5 ETFs That Defied The Market Slump</a></li>
</ul>
Photo: Shutterstock

Broad U.S. Equity ETFs

ETFs

COST

USMV

3 ETFs To Help You Navigate Market Volatility, Recession Risks

HighPeak Energy shares are trading higher following a Q4 adjusted EPS beat.

With growing concern over macroeconomic items like tariffs, Roundhill Investments highlights the potential for a correction and <a href="https://www.benzinga.com/general/market-summary/25/03/44227856/nasdaq-sp-500-hit-6-month-lows-as-recession-fears-grow-whats-driving-markets-monday">a bear market.</a>
What Happened: After optimism for the stock market following Donald Trump's victory in the 2024 presidential election, investors are cautious with fears of<a href="https://www.benzinga.com/general/market-summary/25/03/44216011/us-stocks-likely-to-open-lower-after-trump-hints-at-looming-recession-expert-says-cant-rule-out-a-bear-market-as-indices-inch-towards-correction-territory"> a recession growing.</a>
Trump's recent comments on "a period of transition" and the continued overhang of tariffs on countries like Canada, Mexico and China leading to higher prices for American consumers could be sparking the fears.
A weekly <a href="https://blog.roundhillinvestments.com/roundhill-roundup-march-2025">newsletter </a>from ETF company Roundhill Investments covered the potential of a recession and also how Trump is viewed for the markets. Roundhill CEO Dave Mazza and Roundhill ETF strategist Thomas DiFazio covered the Trump trade and current macroeconomic concerns in a series of charts and thoughts.
"As we march through 2025, the U.S. economy is a mixed bag of solid realized growth coupled with lurking dangers following years of relative calm," the newsletter reads.
The newsletter hits on the recent Trump comments about potential short-term setbacks to achieve long-term goals, much to the potential dismay of investors.
"While the broader market has not yet experienced a correction, let alone a bear market, investors did not seem to appreciate how quickly the ‘Trump bump' would turn to the ‘Trump slump', especially for previous high-flying names."
Dark clouds on the horizon include tariffs and a reacceleration of inflation the report said.
"Mentions of tariffs and trade wars are surging in both company transcripts and news publications to the highest levels on record."
Read Also: <a href="https://www.benzinga.com/etfs/new-etfs/25/02/43862680/roundhill-launches-weeklypay-etfs-with-5-funds-offering-enhanced-payouts">Roundhill Launches WeeklyPay ETFs With 5 Funds Offering Enhanced Payouts</a>
Why It's Important: Mazza and DiFazio said uncertainty around tariffs and economic growth are elevated, but there are still some positives. "On balance, the U.S. economy does not appear to be in major trouble quite yet."
Items like a strong job market, the Manufacturing Purchasing Managers' Index in expansionary territory and the S&amp;P 500 having +17% year-over-year earnings growth in the fourth quarter are positives mentioned.
The report said soft data points like sentiment and confidence are showing lows, while hard data like earnings, GDP, unemployment and retail sales are showing stability for the economy.
"The U.S. economy expanded by 2.8% in 2024, following a 2.9% growth in 2023. While sticky, inflation has decreased from 9.0% year-over-year increases in 2022 to 3.0% today."
Mazza and DiFazio write that the Federal Reserve is now "caught between a rock and a hard place," as they wrestle with inflation fears.
"Walking the fine line between supporting economic growth and reigning in inflation ties the Fed's hands in adjusting interest rates, preventing them from cutting to the extent previously forecasted."
The report noted that a prolonged slowdown in the economy could weigh on profit growth, often a barometer of strength for stocks.
"While the U.S. economy flashes some green lights with solid growth and a resilient labor market, the red flags of escalating tariffs and relentless inflation can't be ignored."
SPY Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500 Index, serves as one of the top barometers of the stock markets and economy. The ETF is down 2.7% on Monday to $560.55 versus a 52-week trading range of $493.86 to $613.23.
The ETF is down 4.1% year-to-date in 2025 and up 9.6% over the last year. The ETF closed at $597.58 on Jan. 17, President Joe Biden's last day in office. Shares are down 6.2% since that date.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/25/03/44226602/walmart-ceo-says-consumers-changing-spending-due-to-inflation-egg-prices-the-money-runs-out-before-the-month-is-gone-people-are-buying-smaller-pack-sizes">Walmart CEO Says Consumers Changing Spending Due To Inflation, Egg Prices: &#8216;The Money Runs Out Before The Month Is Gone … People Are Buying Smaller Pack Sizes&#8217;</a></li>
</ul>
Photo: Shutterstock

Politics

Trump Bump Or Trump Slump? ETF Strategists Say 'Lurking Dangers' Coming After Years Of Calm

In the last three months, 12 analysts have published ratings on Illinois Tool Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $267.08, a high estimate of $318.00, and a low estimate of $245.00. Observing a downward trend, the current average is 1.36% lower than the prior average price target of $270.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1741640470_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Illinois Tool Works. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$260.00</td>
<td>$262.00</td>
</tr>
<tr>
<td>David Raso</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$252.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$262.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$259.00</td>
<td>$266.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$245.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$295.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$266.00</td>
<td>$268.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$265.00</td>
<td>$279.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$265.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$250.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$318.00</td>
<td>$312.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$268.00</td>
<td>$262.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Illinois Tool Works. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Illinois Tool Works compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Illinois Tool Works's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Illinois Tool Works's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ITW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Illinois Tool Works analyst ratings.</a>
<h2>Get to Know Illinois Tool Works Better</h2>
Founded in 1912, Illinois Tool Works has become a diversified industrial manufacturer through acquisitions and innovations that follow customer needs. ITW operates through seven business segments, with no segment representing more than one fifth of revenue. ITW's automotive OEM segment sells vehicle components; its food equipment segment sells commercial kitchen appliances; its test &amp; measurement and electronics segment sells inspection and analysis equipment; its welding segment sells welding equipment and consumables; its polymers &amp; fluids segment sells industrial and consumer adhesives, solvents, and coatings; its construction products segment sells building fasteners and tools; and its specialty products segment sells medical, packaging, HVAC, and airport ground equipment.
<h3>Illinois Tool Works: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Illinois Tool Works's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -1.28%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Illinois Tool Works's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 19.07% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Illinois Tool Works's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 22.36% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Illinois Tool Works's ROA stands out, surpassing industry averages. With an impressive ROA of 4.86%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.44, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Illinois Tool Works Through The Eyes Of 12 Analysts

TBRG

TruBridge shares are trading lower after the company reported worse-than-expected Q4 adjusted EPS results.

Mission Produce shares are trading lower. The company reported Q1 financial results.

Vail Resorts shares are trading higher after the company reported Q2 financial results and beat its EPS estimate.

Press Releases

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Small Cap

Opinion

Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

Health Care

Legal

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)

Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments

Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

Sun Pharma to Acquire Checkpoint Therapeutics

Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders

CKPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Checkpoint Therapeutics, Inc. Is Fair to Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CKPT, RDFN, BLBX on Behalf of Shareholders

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Checkpoint Therapeutics, Inc. - CKPT

AKYA

BCTX

BLBX

CKPT

CRDF

DERM

FBIO

FBIOP

ONCY

PSNL

RCUS

RDFN

TSX:ONC

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Coherus BioSciences

Cellectis S.A. - American Depositary Shares

Cellectis

Coya Therapeutics

Elicio Therapeutics

Elutia

Fate Therapeutics

Invivyd

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Seres Therapeutics

Nkarta

OncoCyte

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Renovaro

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Sutro Biopharma

TScan Therapeutics

Instil Bio

Vor Biopharma

Vaxart

Zentalis Pharmaceuticals, Inc. - common stock

Comments

Checkpoint Therapeutics

Checkpoint Therapeutics (CKPT) オプション

Checkpoint Therapeutics (NASDAQ:CKPT) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル